Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer

BJU International

Volumn 109, Issue 8, 2012, Pages 1183-1192

  Lu, Lanting ^a   Peters, Jaime ^a   Roome, Chris ^b   Stein, Ken ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b Public Health Directorate   (United Kingdom)

Author keywords

Advanced prostate cancer; Cost benefit analysis; Degarelix; Hormonal treatment; Probabilistic sensitivity analysis; Simulation

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE; DEGARELIX; FLUTAMIDE; TRIPTORELIN;

ADVANCED CANCER; AGED; ARTICLE; ASYMPTOMATIC DISEASE; CANCER LOCALIZATION; CANCER SURVIVAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MALE; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT MONITORING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SHORT COURSE THERAPY; UNSPECIFIED SIDE EFFECT;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG THERAPY, COMBINATION; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MODELS, ECONOMIC; OLIGOPEPTIDES; PROSTATIC NEOPLASMS; TESTOSTERONE; TREATMENT OUTCOME; TRIPTORELIN PAMOATE;

EID: 84859452052     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10434.x     Document Type: Article

References (29)

1. Torn ø e CW, Agers ø H, Senderovitz T et al. Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic-pituitary- gonadal axis following treatment with GnRH analogues. Br J Clin Pharmacol 2007; 63: 648-64
2. Westlake S, Cooper N. Office for National Statistics. Cancer incidence and mortality: trends in the United Kingdom and constituent countries, 1993-2004. Health Stat Quart 2008; 38: 33-46
3. The British Association of Urological Surgeons. Section of Oncology: BAUS Cancer Registry, Analyses of Minimum Data Set for Urological Cancers, 1 January to 31 December 2009. London: British Association of Urological Surgeons, 2010
4. The British Association of Urological Surgeons. Section of Oncology: BAUS Cancer Registry, Analyses of Minimum Data Set for Urological Cancers, 1 January to 31 December 2007. London: British Association of Urological Surgeons, 2008
5. Office for National Statistics. Statistical Bulletin: Cancer Survival in the Spearhead Primary Care Trusts of England, 2001-08. London: Office for National Statistics, 2010
6. Klotz L, Boccon-Gibod L, Shore ND et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008; 102: 1531-8
7. Oh WK, Landrum MB, Lamont EB, McNeil BJ, Keating NL. Does oral antiandrogen use before leuteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare? Urology 2010; 75: 642-7
8. NICE. Guide to the Methods of Technology Appraisal. June 2008. Available at: http://www. nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed January 2011
9. Gittelman M, Pommerville PJ, Persson BE, Jensen JK, Olesen TK, for the Degarelix Study Group. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol 2008; 180: 1986-92
10. Van Poppel H, Tombal B, de la Rosette JJ, Persson BE, Jensen JK, Kold Olesen T. Degarelix: a novel gonadotropinreleasing hormone (GnRH) receptor blocker - results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol 2008; 54: 805-13
11. Waxman J, Man A, Hendry WF et al. Importance of early tumour exacerbation in patients treated with long acting analogues of gonadotrophin releasing hormone for advanced prostatic cancer. Br Med J (Clin Res Ed) 1985; 291: 1387-8 (Pubitemid 16212355)
12. Thompson IM, Zeidman EJ, Rodriguez FR. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate. J Urol 1990; 144: 1479-80
13. Boccon-Gibod L, Laudat MH, Dugue MA, Steg A. Cyproterone acetate lead-in prevents initial rise of serum testosterone induced by LHRH analogs in the treatment of metastatic carcinoma of the prostate. Eur Urol 1986; 12: 400-2 (Pubitemid 17212964)
14. Ferring Pharmaceuticals Ltd. Firmagon® (Degarelix) Pharmacoeconomic Evaluation. All Wales Medicines Strategy Group (AWMSG) Health Technology Appraisal Submission. 2009
15. Bayoumi AM, Brown AD, Garber AM. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer. J Natl Cancer Inst 2000; 92: 1731-9
16. European Association of Urology. Guidelines on Prostate cancer. Available at: http://www.uroweb.org/gls/pdf/Prostate%20Cancer%202010%20 June%2017th.pdf. Accessed January 2011
17. Office for National Statistics. Interim Life Tables, United Kingdom, 1980-82 to 2006-08. London: Office for National Statistics, 2009
18. Bennett CL, Matchar D, McCrory D, McLeod DG, Crawford ED, Hillner BE. Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers? Cancer 1996; 77: 1854-61
19. Hollingworth W, Gray DT, Martin BI, Sullivan SD, Deyo RA, Jarvik JG. Rapid magnetic resonance imaging for diagnosing cancer-related low back pain. J Gen Intern Med 2003; 18: 303-12 (Pubitemid 36529049)
20. Kaplan RM, Anderson JP. A general health policy model: update and applications. Health Serv Res 1988; 2 3: 203-35
21. Debruyne FM, Fernandez del Moral P, Geboers AD. LHRH-analogues therapy for metastatic prostate cancer. Prog Clin Biol Res 1988; 260: 27-39
22. Crawford ED, Eisenberger MA, McLeod DG et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419-24 (Pubitemid 19211484)
23. Kuhn JM, Billebaud T, Navratil H et al. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med 1989; 321: 413-8 (Pubitemid 19211483)
24. Curtis L. Unit Costs of Health and Social Care 2008. Canterbury: University of Kent, 2008
25. Joint Formulary Committee. British National Formulary, No. 59. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2010
26. NICE. Metastatic Spinal Cord Compression: Diagnosis and Management of Patients at Risk of or With Metastatic Spinal Cord Compression. London: NICE, 2008
27. Department of Health (UK). NHS Reference Costs 2009. London: Department of Health, 2009
28. Patchell RA, Tibbs PA, Regine WF et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 2005; 366: 643-8 (Pubitemid 41176016)
29. Huddart RA, Rajan B, Law M, Meyer L, Dearnaley DP. Spinal cord compression in prostate cancer: treatment outcome and prognostic factors. Radiother Oncol 1997; 44: 229-36 (Pubitemid 27405146)